The article highlights how Nuage is deploying a suite of proprietary¡y biophysics tools that ‘capture’ intrinsically-disordered proteins in a secondary-structured form to address the challenge of therapeutically targeting a range of racer-driving transcription factors.

This approach has the potential to revolutionise the way that certain tumours are treated and usher in a new wave of transformational targeted cancer therapies.

Nuage Therapeutics is one of the three companies featured in the article, all headquartered at Parc Científic de Barcelona. The city is becoming one of the top areas for biotech research thanks to its well-connected ecosystem of top-tier hospitals, research institutes and global pharmaceutical companies.

You can read the full article here.